Research Grant
[Cite as https://purl.org/au-research/grants/nhmrc/1146192]Brief description Leukemia stem cells (LSC) are often resistant to conventional and targeted therapies and therefore serve as the seed for leukaemia relapse. The overall aim of this project is to use small molecule therapies to block the activity of a particular protein (LSD1) in LSC in order to differentiate them and expose a vulnerability to another epigenetic therapy called a BET inhibitor. Together, these epigenetic therapies will differentiate and eradicate LSC, leading to improved outcome in AML.
Funding Amount $AUD 674,315.07
Funding Scheme Project Grants
Notes New Investigator Grant
- nhmrc : 1146192
- PURL : https://purl.org/au-research/grants/nhmrc/1146192
